# Tolerability of MK0524A Versus Niacin Extended-Release (0524A-054)

> **NCT00378833** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 1300 (actual)

## Conditions studied

- Hypercholesterolemia
- Hyperlipidemia

## Interventions

- **DRUG:** niacin (+) laropiprant
- **DRUG:** niacin

## Key facts

- **NCT ID:** NCT00378833
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07
- **Primary completion:** 2007-03
- **Final completion:** 2007-03
- **Target enrollment:** 1300 (ACTUAL)
- **Last updated:** 2017-02-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00378833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00378833, "Tolerability of MK0524A Versus Niacin Extended-Release (0524A-054)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00378833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*